Report of methamphetamine use and cardiomyopathy in three patients by Roxana Sadeghi et al.
Sadeghi et al. DARU Journal of Pharmaceutical Sciences 2012, 20:20
http://www.darujps.com/content/20/1/20CASE REPORT Open AccessReport of methamphetamine use and
cardiomyopathy in three patients
Roxana Sadeghi1, Khosro Agin1, Maryam Taherkhani1, Leila Najm-Afshar1, Lewis S Nelson2,
Mohammad Abdollahi3 and Shahin Shadnia4,5*Abstract
Background: Methamphetamine (meth) is a stimulant used illegally around the world, including in Iran.
Cardiomyopathy and cardiac failure may occur following chronic meth use and may cause the patients referred
to the emergency department.
Case reports: A 28-year old man and two women, ages 29 and 31-year-old, with a history of meth use, were
admitted to the emergency department with severe dyspnea at rest. Each had sinus tachycardia with tachypnea
and an echocardiogram that showed severe systolic dysfunction consistent with heart failure. Additional evaluation
in the hospital revealed cardiomyopathy with no other etiology other than the meth use.
Conclusion: There are several reports that show an increase in frequency of meth use, suggesting that
cardiomyopathy and acute heart failure may be a new medical concern.
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Substance misuse is a major health problem in all parts
of the world. Methamphetamine (meth) is a synthetic
amine stimulant that is a highly addictive stimulant, and
is currently the most widespread illegal amine drug used
in the United States [1]. Its use has increased during the
past two decades, especially in teenagers [2,3]. The last
report by the Iranian drug control headquarters showed
that only 3.6% of substance users in Iran used meth [4].
However, in recent years the local production of meth
has risen and its price has decreased, resulting in grow-
ing use of the drug. Nonofficial reports estimate that
meth is currently the second or third most widely used
illicit substance in Iran [5].
Chronic use results in a number of medical complica-
tions and fatalities [6]. Meth directly affects multiple
organs, as well as causes hypertension and tachycardia,
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reproduction in any medium, provided the ordysrhythmias, ventricular hypertrophy, pulmonary edema
and hypertension, cerebral stroke and hemorrhage,
seizures, psychosis, and occasionally death may occur
[7]. Due to the combination of some of these effects,
long term users may develop cardiomyopathy. Although
the incidence of methamphetamine cardiomyopathy is
unknown, we report three cases of methamphetamine
cardiomyopathy in Iran.
Case reports
Three patients, a 28-year-old man, and a 29 and 31-year-
old woman, were admitted separately in Loghman Hakim
Hospital, a referral and tertiary care medical center in
Tehran, Iran. All had a chief complain of severe dyspnea at
rest. The 28-year-old man also complained of exertional
chest pain which was typical ischemic chest pain. On
arrival, all of them were conscious and followed com-
mands. None of them had any underlying disease and the
only pertinent positive in their medical history was meth
use, which was supported by a urinary drug screen. The
duration of meth use in the man was one year and was 2
and 3 years in the 29 and 31-year-old woman, respectively.
Vital signs on arrival included: BP: 90/70 mmHg, 100/
60 mmHg and 90/60 mmHg, PR: 120, 104 and 110 beats/
min and RR: 26, 32 and 22 breaths/min, respectively.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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an electrocardiogram (ECG) revealed sinus tachycardia,
poor R wave progression in the pericardial leads, and T
wave inversions in precordial leads in all three patients.
Also, the second patient showed right axis deviation
(135°) and the third patient had QS wave in the inferior
leads. Measurement of cardiac troponin, evaluation of
renal and thyroid function tests, measurement of serum
electrolytes, blood lipids and a complete blood cell count
(CBC) are shown in Table 1. A normal fasting transferrin
saturation test was subsequently performed, ruled out
hemochromatosis as an etiology of the cardiomyopathy.
The 28-year-old man underwent coronary angiography
due to concomitant chest pain, which was normal. All
three patients underwent two-dimensional echocardiog-
raphy with Doppler during the initial evaluation, and
revealed severe decrease in left ventricular ejection frac-
tion (LVEF) in each.
The patients were treated with angiotensin-converting
enzyme inhibitors (ACEIs), beta-adrenergic antagonists,
diuretics and digoxin and were discharged after 7, 10
and 20 days hospitalization. At the time of discharge, theTable 1 Laboratory data of the patients at admission in the h
31-year-old woman 29-year-old woman 28-y
101 (1) 48 (1)
1.5 (1) 1.0 (1)
136 (1) 137 (1)
4.8 (1) 4.9 (1)
8.5 (3) 9.0 (3)
5.1 (3) 4.6 (3)
2.1 (3) 2.0 (3)
73 (1) 68 (1)
15 (1) 8 (1)
14.1 (1) 14.7 (1)
26.0 (1) 28.0 (1)
1.63 (1) 1.8 (1)
10700 (1) 17900 (1)
11.9 (1) 8.1 (1)
34.3 (1) 28.5 (1)
333000 (1) 215000 (1) 2
13 (3) 9 (3)
Normal Normal
Negative Negative
106 (3) 104 (3)
95 (3) 110 (3)
35 (3) 31 (3)
52 (3) 51 (3)
72 (1) 90 (1)
0.4 (3) ND
ND=Not determined.
The data in the parenthesis show the days after admission.2 women were classified as having New York Heart
Association class I (NYHA-I) and the man NYHA-III
heart failure [8]. Outpatient visits were scheduled and
the patients have been followed up for 9, 5 and 6 months
respectively; no clinical or echocardiographic improve-
ments were noted. The man patient was considered for
heart transplantation due to his severe symptoms at rest
despite optimal medical treatment.
Written informed consent was obtained from the
patients for publication of this report and any accom-
panying images.
Discussion
Meth is relatively easy to manufacture making its pro-
duction inexpensive and widely available. Its low cost
and long duration of action have made it a very desirable
drug for use [5]. In addition, its high addictive potential
and stimulant effects have made its use a serious health
problem [9,10].
Meth affects multiple organs, including the cardiovas-
cular system [7]. One report suggests that 40% of young
patients with cardiomyopathy are meth abusers [11]. Inospital and during hospitalization
ear-old man Laboratory parameter (Normal range)
66 (1) Urea (15–45 mg/dL)
1.5 (1) Creatinine (0.7–1.4 mg/dL)
145 (1) Na (135–150 mEq/L)
4.9 (1) K (3.2–5.5 mEq/L)
9.9 (3) Calcium (8.5–10.5 mg/dL)
4.4 (3) Phosphorus (2.5–4.8 mg/dL)
1.9 (3) Magnesium (1.9–2.5 mg/dL)
102 (1) Creatinine phosphokinase (24–195 U/L)
16 (1) CPK-MB (0–24 U/L)
12.6 (1) Prothrombin time (12–14 second)
34.5 (1) Partial thromboplastin time (24–36 second)
1.27 (1) International normalized ratio (up to 1)
14100 (1) White blood cell (4000–10000/μL)
12.4 (1) Hemoglobin (12–14 g/dL)
39.9 (1) Hematocrit (30–45%)
46000 (1) Platelet (150000-350000/μL)
3 (2) Erythrocyte sedimentation rate (0–10 mm/h)
Normal Thyroid function tests
Negative Human immune deficiency virus
248 (3) Total cholesterol levels (mg/dL)
245 (3) Serum triglycerides (mg/dL)
161 (3) LDL cholesterol (mg/dL)
38 (3) HDL cholesterol (mg/dL)
70 (2) Fasting blood sugar (60–110 mg/dL)
0.5 (3) Troponin (adult < 1.3 mg/mL)
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patients presenting to the emergency department with
heart failure [12]. Previous case reports and case series
suggest that meth exposure is potentially associated with
structural and functional changes of myocytes, as well as
clinical manifestations of cardiomyopathy and congestive
heart failure [13]. In Iran, the frequency of meth use
especially within the young population has increased in
the recent years [14,15], raising concerns for the future
development of cardiomyopathy and acute decompen-
sate heart failure in this group.
Diagnosing the etiology of dyspnea can be difficult, in
part because several disorders may coexist. However, our
patients were young and had no underlying medical pro-
blems except for meth use. The clinical evaluation found
only left ventricular systolic dysfunction in all three
patients. Although endomyocardial biopsies were not
performed, the failure of clinical or echocardiographic
improvement over time supports the diagnosis of meth-
associated cardiomyopathy.
The most probably mechanisms for meth cardiotoxi-
city relates to the potent central and peripheral sym-
pathomimetic effects of meth [16]. The increase in
circulating catecholamine levels caused by this drug
causes coronary vasospasm, persistent tachycardia and
hypertension, and/or direct myocardial toxicity [17-19].
As in our cases, patients with meth-associated cardio-
myopathy have a significantly lower LVEF or more se-
vere ventricular dilation when compared with patients
with cardiomyopathy from other causes [11,20]. As there
is no antidote for the treatment of cardiac toxicity of
meth use in various countries [21,22], some cardiac
effects of its use, like myocyte hypertrophy and fibrosis
are relatively irreversible [23], and cardiac toxicity may
result in sudden and unexpected death [24]. By the way,
recovery of left ventricular dysfunction in patients with
meth-induced cardiomyopathy has been described [25],
although recovery of cardiac function did not occur in
any of our cases during follow up.
Recognition of cardiomyopathy and acute heart failure
as a complication associated with the meth use may be a
new medical concern.
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